Regeneron Pharmaceuticals on Monday announced plans to purchase genetic testing company 23andMe for $256 million.

Regeneron Pharmaceuticals said on Monday it will buy genetic testing firm 23andMe Holding for $256 million through a bankruptcy auction, and promised to prioritize the ethical use of customers' DNA da...

Regeneron said Monday it will “prioritize the privacy, security and ethical use” of the personal DNA data from about 15 million people in a $256 million deal to acquire assets of bankrupt 23andMe Hold...